High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
The impact of serum levels of soluble programmed cell death ligand 1 (sPD-L1) on prognosis in patients with Epstein-Barr virus-associated malignancies has never been investigated. We prospectively measured pre- and post-treatment serum sPD-L1 levels and evaluated their prognostic value in 97 patients with newly diagnosed, early stage extranodal NK/T-cell lymphoma (ENKTCL) treated with asparaginase-based chemotherapy followed by radiotherapy. For predicting survival outcomes, serum sPD-L1 levels of 3.23 ng/mL and 1.12 ng/mL were respectively identified for pre- and post-treatment cut-off levels. Patients with high pretreatment (>3.23 ng/mL) had shorter progression-free survival (PFS) and overall survival (OS). In a multivariate survival analysis, post-treatment sPD-L1 >1.12 ng/mL, treatment response (complete vs. non-complete response), and stage II disease were independent prognostic factors for shorter PFS and OS. In patients with a complete response, post-treatment sPD-L1 >1.12 ng/mL was associated with shorter PFS and OS. In patients with high pretreatment sPD-L1 levels (>3.23 ng/mL), low post-treatment sPD-L1 level (≤1.12 ng/mL) correlated with longer PFS and OS. Our data suggest the post-treatment sPD-L1 level is a potent biomarker for predicting early relapse and poor prognosis in early stage ENKTCL patients treated with asparaginase, and may be a useful marker of minimal residual disease.
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Hua
H
Wang
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Liang
L
Wang
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Wen-Jian
WJ
Liu
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Zhong-Jun
ZJ
Xia
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Hui-Qiang
HQ
Huang
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Wen-Qi
WQ
Jiang
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Zhi-Ming
ZM
Li
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.|State Key Laboratory of Oncology in South China, Guangzhou, 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Yue
Y
Lu
D000328:Adult; D060890:B7-H1 Antigen / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood* / Q000401:mortality / Q000628:therapy*; D008297:Male; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate
D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human
asparaginase; extranodal NK/T cell lymphoma; minimal residual disease; prognosis; soluble programmed cell death ligand 1